<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00750633</url>
  </required_header>
  <id_info>
    <org_study_id>C-07-13</org_study_id>
    <nct_id>NCT00750633</nct_id>
  </id_info>
  <brief_title>A Phase III Study of an Otic Formulation in Acute Otitis Externa</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if an otic formulation is safe and effective for
      the treatment of acute otitis externa (AOE).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Cure</measure>
    <time_frame>Day 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Cure</measure>
    <time_frame>Day 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Microbiological Success</measure>
    <time_frame>Day 12</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">990</enrollment>
  <condition>Acute Otitis Externa</condition>
  <arm_group>
    <arm_group_label>Moxidex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Moxidex otic solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moxifloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Moxifloxacin otic solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dexamethasone phosphate otic solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxidex otic solution</intervention_name>
    <description>4 drops in the infected ear(s) twice daily (morning and evening) for 7 days</description>
    <arm_group_label>Moxidex</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin otic solution</intervention_name>
    <description>4 drops in the infected ear(s) twice daily (morning and evening) for 7 days</description>
    <arm_group_label>Moxifloxacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone phosphate otic solution</intervention_name>
    <description>4 drops in the infected ear(s) twice daily (morning and evening) for 7 days</description>
    <arm_group_label>Dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Tympanostomy tubes</intervention_name>
    <description>Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media with effusion in children</description>
    <arm_group_label>Moxidex</arm_group_label>
    <arm_group_label>Moxifloxacin</arm_group_label>
    <arm_group_label>Dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of AOE based on clinical observation and of presumed bacterial
             origin

          -  A minimum combined score of â‰¥4 in at least 1 affected ear at the Day 1 exam for
             tenderness, erythema, and edema

          -  Other protocol-defined inclusion criteria may apply

        Exclusion Criteria:

          -  Duration of pretherapy signs or symptoms of AOE greater than four (4) weeks

          -  Presence of a tympanostomy tube or perforated tympanic membrane in the treated ear(s).
             Patients with a history of tympanic membrane perforation should not be enrolled unless
             the absence of a current perforation can be confirmed at Visit 1 prior to enrollment

          -  Clinically diagnosed chronic suppurative otitis media, acute otitis media, acute
             otorrhea in patients with tympanostomy tubes, or malignant otitis externa

          -  Known or suspected ear infection of fungal or mycobacterial origin

          -  Prior otologic surgery within 6 months of study entry

          -  Seborrheic dermatitis or other skin conditions of the external auditory canal

          -  Current or prior history of an immunosuppressive disorder (e.g., HIV positive) or
             current immunosuppressive therapy (e.g., cancer chemotherapy) or known acute or
             chronic renal disorders or active hepatitis

          -  Diabetic patients (controlled or uncontrolled) based upon assessment by Investigator

          -  Any systemic disease or disorder, complicating factor or structural abnormality that
             would negatively affect the conduct or outcome of the study [e.g., cleft palate
             (including repairs), Downs Syndrome, and cranial facial reconstruction]

          -  Any current known or suspected infection (other than AOE) requiring systemic
             antimicrobial therapy

          -  Use of prohibited medications or inadequate washout of any medication listed in
             protocol

          -  Concomitant use of topical or oral analgesics (i.e., NSAIDs and aspirin products)
             which may have anti inflammatory effects. Patients on low dose aspirin therapy (81 mg
             per day) at the time of enrollment may be enrolled and continue the low dose aspirin
             during the study. Use of acetaminophen (&quot;Tylenol&quot;) is permitted during the trial

          -  Other protocol-defined exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Contact Alcon Call Center</last_name>
    <role>Study Director</role>
    <affiliation>1-888-451-3937</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2008</study_first_submitted>
  <study_first_submitted_qc>September 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2008</study_first_posted>
  <disposition_first_submitted>November 28, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>November 28, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 30, 2012</disposition_first_posted>
  <last_update_submitted>November 29, 2012</last_update_submitted>
  <last_update_submitted_qc>November 29, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>swimmer's ear</keyword>
  <keyword>ear drops</keyword>
  <keyword>ear infection</keyword>
  <keyword>ear pain</keyword>
  <keyword>ear inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Otitis</mesh_term>
    <mesh_term>Otitis Externa</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

